OrbusNeich Medical Group Holdings Limited (HK:6929)
:6929
Want to see HK:6929 full AI Analyst Report?
Top Page
OrbusNeich Medical Group Holdings Limited
(6929)
Select Model
Select Model
Rating:78Outperform
Price Target:
HK$4.50
▲(1.35% Upside)
Action:Reiterated
Date:05/12/26
The score is driven primarily by strong financial quality (exceptionally low leverage and steady profitability) and an attractive valuation (very low P/E with a modest dividend). These positives are tempered by weakening cash generation (very low free cash flow in 2024–2025) and an overbought technical setup (RSI ~79) despite an uptrend.
Positive Factors
Balance sheet strength
Very low leverage and a large equity base give OrbusNeich durable financial flexibility. This conservative capital structure reduces refinancing and solvency risk, supports investment in manufacturing, regulatory approvals and commercialization, and underpins resilience through cyclical healthcare spending.
Negative Factors
Weakened cash conversion
Operating cash flow now covers only a modest portion of net income and free cash flow is very low, reducing internal funding for capex, regulatory submissions and inventory. Persistently weak cash conversion increases reliance on external financing or slower organic growth over coming quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance sheet strength
Very low leverage and a large equity base give OrbusNeich durable financial flexibility. This conservative capital structure reduces refinancing and solvency risk, supports investment in manufacturing, regulatory approvals and commercialization, and underpins resilience through cyclical healthcare spending.
Read all positive factors
OrbusNeich Medical Group Holdings Limited (6929) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$3.33B
Dividend Yield2.7%
Average Volume (3M)176.23K
Price to Earnings (P/E)9.2
Beta (1Y)0.59
Revenue Growth9.88%
EPS Growth5.65%
CountryHK
Employees1,331
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)0.05
Shares Outstanding827,968,300
10 Day Avg. Volume244,250
30 Day Avg. Volume176,233
Financial Highlights & Ratios
PEG Ratio1.57
Price to Book (P/B)0.93
Price to Sales (P/S)2.13
P/FCF Ratio333.81
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$5.30Price Target Upside19.37% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.06
Revenue Forecast (FY)HK$197.73M
OrbusNeich Medical Group Holdings Limited Business Overview & Revenue Model
Company Description
OrbusNeich Medical Group Holdings Limited, an investment holding company, manufactures, trades in, sells, and markets medical devices/instruments used for the treatment of coronary and peripheral vascular diseases in Japan, Europe, the Middle East...
How the Company Makes Money
OrbusNeich makes money primarily by selling interventional cardiovascular medical devices used in coronary procedures. Its core revenue stream is product sales to hospitals and healthcare providers (often via catheterization labs), with pricing an...
OrbusNeich Medical Group Holdings Limited Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
92
Very Positive
Cash Flow
54
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 180.45M | 164.10M | 153.87M | 136.82M | 116.46M |
| Gross Profit | 122.43M | 114.47M | 106.50M | 92.46M | 81.17M |
| EBITDA | 42.78M | 36.76M | 53.97M | 27.14M | 8.31M |
| Net Income | 41.90M | 39.72M | 45.07M | 18.49M | -4.44M |
Balance Sheet | |||||
| Total Assets | 452.85M | 431.01M | 410.14M | 351.06M | 268.53M |
| Cash, Cash Equivalents and Short-Term Investments | 218.68M | 248.59M | 256.21M | 247.94M | 175.89M |
| Total Debt | 3.91M | 4.20M | 7.46M | 4.03M | 67.69M |
| Total Liabilities | 38.71M | 36.63M | 40.73M | 28.49M | 85.42M |
| Stockholders Equity | 413.00M | 393.31M | 368.40M | 322.57M | 183.11M |
Cash Flow | |||||
| Free Cash Flow | 1.15M | 1.84M | 15.55M | 20.10M | 18.36M |
| Operating Cash Flow | 19.53M | 13.11M | 23.03M | 23.43M | 20.50M |
| Investing Cash Flow | 15.90M | 8.65M | -52.31M | -169.32M | -5.22M |
| Financing Cash Flow | -29.35M | -18.96M | 884.00K | 57.44M | 146.31M |
OrbusNeich Medical Group Holdings Limited Technical Analysis
Neutral
4.44
Price Trends
3.90
Positive
3.82
Positive
4.11
Negative
Market Momentum
0.08
Positive
49.53
Neutral
16.88
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6929, the sentiment is Neutral. The current price of 4.44 is above the 20-day moving average (MA) of 4.07, above the 50-day MA of 3.90, and above the 200-day MA of 4.11, indicating a neutral trend. The MACD of 0.08 indicates Positive momentum. The RSI at 49.53 is Neutral, neither overbought nor oversold. The STOCH value of 16.88 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:6929.
OrbusNeich Medical Group Holdings Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | HK$3.33B | 9.15 | 10.21% | 2.70% | 9.88% | 5.65% | |
69 Neutral | HK$7.40B | 21.45 | 11.20% | ― | 25.24% | 7.29% | |
67 Neutral | HK$1.74B | 18.55 | 3.68% | 7.46% | 7.11% | -34.66% | |
66 Neutral | HK$14.17B | ― | 5.12% | ― | ― | ― | |
62 Neutral | HK$15.65B | 12.88 | 6.64% | 4.58% | 2.34% | -22.25% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
HK:6929
OrbusNeich Medical Group Holdings Limited
4.05
0.46
12.81%
HK:1066
Shandong Weigao Group Medical Polymer Co
3.52
-2.05
-36.84%
HK:1358
PW Medtech Group Ltd.
1.18
0.20
20.65%
HK:1501
Shanghai Kindly Medical Instruments Co., Ltd. Class H
34.90
9.40
36.86%
HK:6699
Angelalign Technology Inc.
73.55
22.53
44.17%
OrbusNeich Medical Group Holdings Limited Corporate Events
OrbusNeich Sets 2026 AGM to Approve Dividend, Board Mandates and Share Issuance Flexibility
Apr 13, 2026
OrbusNeich Medical Group Holdings Limited has called its annual general meeting for June 8, 2026, in Hong Kong, where shareholders will review the audited financial statements for the year ended December 31, 2025, and receive reports from the boar...
OrbusNeich Delivers Higher 2025 Profit and Boosts Dividend Despite Margin Pressure
Mar 12, 2026
OrbusNeich Medical Group Holdings Limited reported a 10.0% year-on-year increase in revenue to US$180.5 million for the year ended December 31, 2025, with gross profit rising 7.0% to US$122.4 million despite some margin compression. Net profit att...
OrbusNeich Declares HKD 0.12 Final Dividend for 2025 Financial Year
Mar 12, 2026
OrbusNeich Medical Group Holdings has proposed a final ordinary cash dividend of HKD 0.12 per share for the financial year ended 31 December 2025, underscoring its intention to return capital to shareholders. The distribution, subject to sharehold...
OrbusNeich Sets March 12 Board Meeting to Approve 2025 Annual Results and Consider Final Dividend
Mar 2, 2026
OrbusNeich Medical Group Holdings Limited has scheduled a board meeting for March 12, 2026 to review and approve the annual results for the year ended December 31, 2025, and to consider the publication of those results. The board will also deliber...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.